Literature DB >> 2910745

Liver function tests in patients with computed tomography demonstrated hepatic metastases.

M D Ottmar1, R L Gonda, K J Leithauser, O H Gutierrez.   

Abstract

One hundred patients with computed tomographic (CT) evidence of liver metastases (and confirmation by biopsy or progression of disease) had serum levels of alkaline phosphatase, serum glutamic oxaloacetic transaminase, and serum glutamic pyruvic transaminase measured within two weeks of scanning. All three enzymes were within the normal range in 33% of patients. Even with advanced involvement (defined as three or more metastatic lesions over 3 cm in diameter), 20% of patients had normal levels of all three liver enzymes. Although liver function tests (LFTs) (enzyme levels) are inexpensive and simple to perform, they failed to detect a significant number of patients with liver metastases.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2910745     DOI: 10.1007/BF01889155

Source DB:  PubMed          Journal:  Gastrointest Radiol        ISSN: 0364-2356


  34 in total

1.  Diagnostic value of gamma-glutamyl transpeptidase and alkaline phosphatase in liver metastases.

Authors:  H Baden; B Andersen; G Augustenborg; H K Hanel
Journal:  Surg Gynecol Obstet       Date:  1971-11

2.  Improved detection of focal lesions with computerized tomographic examination of the liver using ethiodized oil emulsion (EOE-13) liver contrast.

Authors:  P H Sugarbaker; M Vermess; J L Doppman; D L Miller; R Simon
Journal:  Cancer       Date:  1984-10-15       Impact factor: 6.860

3.  Liver scintigrams compared with alkaline phosphatase and BSP determinations in the detection of metastatic carcinoma.

Authors:  S G Jhingran; L Jordan; M F Jahns; T P Haynie
Journal:  J Nucl Med       Date:  1971-05       Impact factor: 10.057

Review 4.  Hepatic resection for metastatic cancer.

Authors:  R S Jones
Journal:  Surg Annu       Date:  1985

5.  A prospective study of hepatic imaging in the detection of metastatic disease.

Authors:  T J Smith; M M Kemeny; P H Sugarbaker; A E Jones; M Vermess; T H Shawker; B K Edwards
Journal:  Ann Surg       Date:  1982-04       Impact factor: 12.969

6.  A multifactorial analysis of prognostic factors in patients with liver metastases from colorectal carcinoma.

Authors:  C J Lahr; S J Soong; G Cloud; J W Smith; M M Urist; C M Balch
Journal:  J Clin Oncol       Date:  1983-11       Impact factor: 44.544

7.  An analysis of imaging studies and liver function tests to detect hepatic neoplasia.

Authors:  T J McGarrity; T Samuels; F A Wilson
Journal:  Dig Dis Sci       Date:  1987-10       Impact factor: 3.199

8.  Subclinical hepatic toxicity during combination chemotherapy for breast cancer.

Authors:  C A Larroquette; G N Hortobagyi; A U Buzdar; F A Holmes
Journal:  JAMA       Date:  1986-12-05       Impact factor: 56.272

9.  Liver function tests. A study in patients with imaging-demonstrated metastases.

Authors:  J Mathews; J D Slavin; R P Spencer
Journal:  Clin Nucl Med       Date:  1986-05       Impact factor: 7.794

10.  Biological appraisal of liver status in adenocarcinomas.

Authors:  P Canal; R Bugat; P Fernet; J Cassigneul; G Soula
Journal:  Tumori       Date:  1983-12-31
View more
  3 in total

1.  Serological diagnostic factors for liver metastasis in patients with colorectal cancer.

Authors:  Xiong-Zhi Wu; Feng Ma; Xue-Lin Wang
Journal:  World J Gastroenterol       Date:  2010-08-28       Impact factor: 5.742

2.  Current diagnostic and therapeutic approaches for colorectal cancer liver metastasis.

Authors:  K A Paschos; N Bird
Journal:  Hippokratia       Date:  2008-07       Impact factor: 0.471

3.  A single-institutional experience with low dose stereotactic body radiation therapy for liver metastases.

Authors:  Roman O Kowalchuk; Michael R Waters; K Martin Richardson; Kelly M Spencer; James M Larner; C R Kersh
Journal:  Rep Pract Oncol Radiother       Date:  2020-10-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.